Literature DB >> 9479280

Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.

R C Tripathi1, J Li, B J Tripathi, K V Chalam, A P Adamis.   

Abstract

PURPOSE: This study aimed to quantitate and compare the concentration of vascular endothelial growth factor (VEGF) in aqueous humor samples from patients with neovascular glaucoma (NVG), primary open-angle glaucoma (POAG), and cataract, as well as in serum samples of healthy human subjects.
METHODS: The authors collected aqueous humor samples by using their previously published technique of limbal paracentesis. The authors determined the concentration of VEGF by using a competitive enzyme immunoassay system and four-parameter logistic curve fitting and performed statistical analysis by using the Mann-Whitney-Wilcoxon test.
RESULTS: The authors detected VEGF in 12 of 12 samples from patients with NVG (mean +/- standard error of the mean, 29.267 +/- 7.350 ng/ml), 15 of 28 samples from patients with POAG (0.726 +/- 0.204 ng/ml), 4 of 20 aqueous humor samples from patients with cataract (0.257 +/- 0.043 ng/ml), and 16 of 16 human serum samples (20.246 +/- 1.568 ng/ml). The mean concentration of VEGF in aqueous humor of patients with NVG was 40- and 113-fold higher than that in patients with POAG and cataract, respectively, and the difference was statistically significant (P < 0.01). The VEGF level in patients with POAG was elevated compared with that in patients with cataract (P < 0.05). Although the mean concentration of VEGF in aqueous humor of patients with NVG was approximately 1.45-fold higher than that in serum, the difference was not significant (P > 0.05).
CONCLUSION: The authors' findings show that patients with NVG had a significantly increased level of VEGF in the aqueous humor and implicate VEGF as an important factor in the pathogenesis of intraocular neovascularization in these patients. The authors discuss the possible role of the ciliary epithelium, in addition to retina, in the production of VEGF and the complementary function of basic fibroblast growth factor and other growth factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479280     DOI: 10.1016/s0161-6420(98)92782-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  56 in total

1.  Combined pars plana vitrectomy and Baerveldt glaucoma implant placement for refractory glaucoma.

Authors:  Thalmon R Campagnoli; Sung Soo Kim; William E Smiddy; Steve J Gedde; Donald L Budenz; Richard K Parrish; Paul F Palmberg; William Feuer; Wei Shi
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

Review 2.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

Review 3.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-02

4.  The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy.

Authors:  Y Sassa; S Yoshida; K Ishikawa; R Asato; T Ishibashi; T Kono
Journal:  Eye (Lond)       Date:  2016-02-26       Impact factor: 3.775

5.  A 65-year-old man with decreased vision OD.

Authors:  Meghomala Das; Manish Gupta; Robert Harvey; Sourjya Kar
Journal:  Digit J Ophthalmol       Date:  2008-06-15

6.  Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration.

Authors:  Sobha Sivaprasad
Journal:  Clin Ophthalmol       Date:  2008-06

7.  Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization.

Authors:  Meng-Ke Yuan; Yong Tao; Wen-Zhen Yu; Wang Kai; Yan-Rong Jiang
Journal:  Mol Vis       Date:  2010-08-25       Impact factor: 2.367

Review 8.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

9.  Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma.

Authors:  Tae Hoon Lim; Soong Hwan Bae; Young Jae Cho; Jun Haeng Lee; Hwang Ki Kim; Yong Ho Sohn
Journal:  Korean J Ophthalmol       Date:  2009-09-08

10.  Intravitreal bevacizumab for the treatment of neovascular glaucoma associated with central retinal artery occlusion.

Authors:  Min Sagong; Jinseon Kim; Woohyok Chang
Journal:  Korean J Ophthalmol       Date:  2009-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.